Ertapenem
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Ertapenem: From Gram-Negative Bacterial Infections to Bacterial Arthritis
One-Sentence Summary
Ertapenem is a broad-spectrum carbapenem antibiotic originally approved for serious gram-negative bacterial infections, including complicated intra-abdominal infections, community-acquired pneumonia, complicated urinary tract infections, and skin/skin structure infections. The TxGNN model predicts it may be effective for Bacterial Arthritis, with 0 clinical trials and 10 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Serious gram-negative bacterial infections (intra-abdominal, pneumonia, UTI, skin/skin structure) |
| Predicted New Indication | Bacterial Arthritis |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L3 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not formally documented in this Evidence Pack. Based on established pharmacology, ertapenem is a 1-β-methyl carbapenem that exerts bactericidal activity by broadly binding to penicillin-binding proteins (PBPs 2 and 3), thereby inhibiting bacterial cell wall synthesis. It demonstrates potent activity against ESBL-producing organisms, anaerobes, and a wide range of gram-negative bacteria — including Klebsiella pneumoniae, Prevotella spp., and Citrobacter spp. — all of which are established pathogens in bacterial (septic) arthritis.
The pharmacokinetic profile of ertapenem is particularly relevant to joint infections. Its long half-life (~4 hours) supports once-daily dosing, making it well suited for outpatient parenteral antimicrobial therapy (OPAT). Bone and joint infections characteristically require prolonged antibiotic courses (6–12 weeks), and agents requiring only once-daily administration substantially reduce the burden on both patients and healthcare systems. Published OPAT cohorts confirm that bone and joint infections are among the most common long-term indications for outpatient ertapenem use.
Multiple case reports document successful ertapenem-based treatment of septic arthritis caused by organisms within its spectrum, including Klebsiella pneumoniae septic wrist arthritis, Clostridium paraputrificum native shoulder septic arthritis and osteomyelitis, and Prevotella bivia septic knee arthritis. While formal Phase 2/3 randomised trials in bacterial arthritis are absent, the confluence of mechanistic rationale, favourable pharmacokinetics, and real-world case evidence collectively supports the plausibility of this TxGNN prediction.
Clinical Trial Evidence
Currently no related clinical trials registered for ertapenem in bacterial arthritis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24709258 | 2014 | Cohort Study | Antimicrobial Agents and Chemotherapy | Retrospective cohort of 306 OPAT patients; bone and joint infections were among the most common indications for long-term outpatient ertapenem; safety and efficacy confirmed over 2010–2013 |
| 31220276 | 2019 | Cohort Study | Journal of Antimicrobial Chemotherapy | Subcutaneous ertapenem as prolonged suppressive therapy in 10 patients with prosthetic joint infection or chronic osteomyelitis who could not undergo optimal surgery |
| 39193962 | 2024 | Retrospective Study | Clinical Laboratory | Pathogen distribution and antimicrobial resistance in bone and joint infections in children under 4 years; contextualises ertapenem spectrum against relevant paediatric pathogens |
| 41878879 | 2026 | Comparative Study | Journal of Antimicrobial Chemotherapy | Evaluated temocillin as alternative to carbapenems (including ertapenem) for bone/joint infections due to 3GC-resistant Enterobacterales; reinforces carbapenem as standard-of-care reference |
| 22233826 | 2011 | Case Report | Journal of Chemotherapy | Klebsiella pneumoniae septic wrist arthritis successfully treated with ertapenem combined with levofloxacin |
| 31352398 | 2019 | Case Report | BMJ Case Reports | Citrobacter koseri septic arthritis with osteomyelitis in diabetic foot successfully treated with ertapenem; highlights gram-negative spectrum relevance in high-risk populations |
| 37578166 | 2023 | Case Report + Review | Journal of Investigative Medicine High Impact Case Reports | Prevotella bivia septic knee arthritis in an immunocompetent adult; literature review includes ertapenem as an effective option for anaerobic gram-negative septic arthritis |
| 31585203 | 2020 | Case Report | Anaerobe | Clostridium paraputrificum native shoulder septic arthritis and osteomyelitis; ertapenem-based therapy following arthroscopic irrigation and debridement |
| 38924836 | 2024 | In Vitro / Pharmacology | Diagnostic Microbiology and Infectious Disease | Auranofin restores ertapenem susceptibility against carbapenem-resistant E. coli via synergistic mechanism; relevant to potential resistant pathogen scenarios in joint infections |
| 29183082 | 2017 | Review | JAMA | Review of hidradenitis suppurativa diagnosis and treatment; limited direct relevance to bacterial arthritis — included as background on gram-positive skin/soft-tissue infections in the same anatomical territory |
India Market Information
Ertapenem is currently not marketed in India. No drug licenses or product registrations are on record.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No registrations found |
Safety Considerations
Drug Interactions: Ertapenem has 38 documented drug interactions in the DDInter database. Notable interactions include:
- Major interaction:
- Bupropion — carbapenems are known to significantly reduce serum valproate/antiepileptic concentrations; co-administration with bupropion (which lowers seizure threshold) may substantially increase seizure risk
- Moderate interactions:
- Picosulfuric acid
- Polyethylene glycol (3350 with electrolytes)
- Sodium sulfate
- Interactions of uncertain severity (selected examples): Calcitriol, Pantoprazole, Doxycycline, Morphine, Metformin, Omeprazole, Vancomycin, Metronidazole, Ondansetron, Metoclopramide
Full safety data including key warnings and contraindications are not available in this Evidence Pack. Please refer to the official package insert for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: While mechanistic reasoning, favourable pharmacokinetics, and a growing body of real-world case evidence support ertapenem’s applicability in bacterial arthritis, the current evidence base is entirely observational or anecdotal (L3), with no registered clinical trials specifically designed for this indication. Furthermore, ertapenem is not currently marketed in India, which constitutes a significant barrier to near-term clinical translation.
To proceed, the following is needed:
- Formal MOA documentation from DrugBank API or published pharmacology reviews
- Full package insert extraction for warnings, contraindications, and dosing guidance (currently a blocking data gap)
- At least one prospective clinical trial or large structured observational cohort evaluating ertapenem specifically in bacterial (septic) arthritis
- Regulatory pathway assessment for ertapenem market entry or named-patient access in India
- India-specific epidemiological data on septic arthritis pathogens to confirm that ertapenem’s spectrum matches locally prevalent organisms
- Hypoalbuminaemia screening protocol, as evidence suggests suboptimal ertapenem exposure (due to high protein binding) in patients with serum albumin < 2.5 g/dL — particularly relevant in hospitalised patients with septic arthritis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.